TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00497601
Drug: Amphotericin B in fat emulsion
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
Study: NCT02231021
Drug: alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alogliptin 25 mg add-on background medication metformin
Study: NCT00681772
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg, 10mg or 20mg taken 1 hours before sexual intercourse
Study: NCT02231021
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pioglitazone 30 mg add-on background medication metformin
Study: NCT02231021
Drug: alogliptin + pioglitazone
Normalized name: alogliptin / pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
Study: NCT04231136
Drug: Tegoprazan 50 mg
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg tablet
Study: NCT03011320
Drug: 99mTc-Etarfolatide
Normalized name: technetium (99mTc) etarfolatide
DrugBank: Etarfolatide (DB11810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
Study: NCT00717054
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
Study: NCT00717054
Drug: Scopolamine
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
Study: NCT00760669
Drug: Infliximab; observational study
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is an observational study. Participants with RA, AS and PA receiving induction intravenous infusions (a fluid or a medicine delivered into a vein by way of a needle) of infliximab will be observed. Participants with RA will receive infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks (maintenance) thereafter up to 30 weeks. Participants with AS and PA will receive 5 mg/kg infliximab as an intravenous infusion over 2-hour period followed by additional doses at 2 and 6 weeks up to 24-30 weeks and 30 weeks, respectively.
Study: NCT02473848
Drug: ingenol mebutate 500 ucg
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
Study: NCT02939326
Drug: EB-001 injection
Normalized name: BOTULINUM NEUROTOXIN SEROTYPE E (BONT/E) (EB-001)
DrugBank: ANEB-001 (DB18908)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04918524
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
Study: NCT04918524
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
Study: NCT04918524
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
Study: NCT04013555
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flavored effervescent formulation
Study: NCT04013555
Drug: Tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral slurry form
Study: NCT01195766
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab in addition with ESHAP therapy
Study: NCT02323789
Drug: Mesenchymal stromal cells
Normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC-MSC: a cell product containing mesenchymal stromal cells. Mesenchymal stromal cells are adherent non-haematopoietic multipotent cells that are expanded from bone marrow from healthy donors, using platelet lysate as source of growth factor.
Study: NCT01791088
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01639807
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost (0.005%) eye drops, once daily in the evening
Study: NCT02151058
Drug: Experimental Mouth Rinse
Normalized name: moth bean extract
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 10 mL for 60 seconds with the investigational product.
Study: NCT00809185
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.
Study: NCT00152698
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03021486
Drug: Chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03021486
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04608045
Drug: CPX-POM
Normalized name: CPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-POM
Study: NCT01631214
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 70 mg tablet taken once a week
Study: NCT01631214
Drug: Placebo to Romosozumab
Normalized name: romosozumab
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by subcutaneous injection once a month during the double-blind treatment phase.
Study: NCT02611505
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
Study: NCT00036660
Drug: SarCNU
Normalized name: SarCNU
DrugBank: 2-chloroethyl-3-sarcosinamide-1-nitrosourea (DB11688)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03117751
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally (PO).
Study: NCT03117751
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously (IV).
Study: NCT03117751
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT03117751
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or intramuscularly (IM) .
Study: NCT03117751
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or by subcutaneous injection (SQ).
Study: NCT03117751
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO.
Study: NCT03117751
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV.
Study: NCT03117751
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO.
Study: NCT03117751
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or subcutaneously (SQ).
Study: NCT03117751
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO.
Study: NCT03117751
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT03117751
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV.
Study: NCT01636076
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: delivered via Accuhaler®
Study: NCT02052180
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
Study: NCT02052180
Drug: Marcaine (Control)
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
Study: NCT00723060
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
Study: NCT04368559
Drug: Rezafungin for Injection
Normalized name: Rezafungin
DrugBank: Rezafungin (DB16310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antifungal therapy
Study: NCT04368559
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral antifungal therapy
Study: NCT04368559
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral antifungal therapy
Study: NCT01130831
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04368559
Drug: Trimethoprim-sulfamethoxazole (TMP/SMX)
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral antibacterial therapy
Study: NCT03940703
Drug: Tepotinib
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants were administered with Tepotinib orally once daily at a dose of 500 mg.
Study: NCT03940703
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants received Osimertinib at a dose of 80 mg orally once daily.
Study: NCT00380601
Drug: MRA(Tocilizumab)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg/4 weeks
Study: NCT00745004
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
Study: NCT03117751
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO.
Study: NCT03117751
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV.
Study: NCT03117751
Drug: Nelarabine
Normalized name: Nelarabine
DrugBank: Nelarabine (DB01280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV.
Study: NCT03117751
Drug: Thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants with mercaptopurine-related pancreatitis. Given PO.
Study: NCT03117751
Drug: Asparaginase Erwinia chrysanthemi (recombinant)-rywn
Normalized name: asparaginase erwinia chrysanthemi (recombinant)-rywn
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).
Study: NCT03117751
Drug: Calaspargase Pegol
Normalized name: Calaspargase pegol
DrugBank: Calaspargase pegol (DB14730)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
Study: NCT04270526
Drug: Bicarbonate protocol
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradetrussor treatment with 50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
Study: NCT03453164
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab was administered intravenously starting on Day 15-22 at a dose of 3 mg/kg (body weight) or 240 mg/body every 2 weeks to a total of 6 courses of administration.
Study: NCT00055393
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18 subjects in this randomly controlled double blind study received bupropion.
Study: NCT02473250
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.
Study: NCT02441517
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
Study: NCT03814642
Drug: Clopidogrel 75 mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg tablet
Study: NCT03814642
Drug: Tegoprazan 50 mg
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg tablet
Study: NCT03917043
Drug: APG-2449
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, multiple dose cohorts, oral administration every day (QD) of a 28-day cycle
Study: NCT03814642
Drug: Esomeprazole 20 mg
Normalized name: esomeprazole 20 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 20 mg tablet
Study: NCT03417999
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose-escalation of atomized intranasal dexmedetomidine
Study: NCT02897830
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).
Study: NCT02897830
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).~Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles
Study: NCT04247542
Drug: Ibezapolstat
Normalized name: Ibezapolstat
DrugBank: Ibezapolstat (DB16189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational antibacterial agent
Study: NCT04247542
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator
Study: NCT03432676
Drug: Epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03954366
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rucaparib 600 mg BID commencing on Day 5 until Day 23.
Study: NCT03954366
Drug: Oral Contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.
Study: NCT00904943
Drug: Topiramate Capsules, 25 mg
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 x 25 mg Capsules
Study: NCT00346580
Drug: Nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01148368
Drug: fimasartan
Normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single administration of fimasartan 120mg
Study: NCT03085095
Drug: Relugolix
Normalized name: Relugolix
DrugBank: Relugolix (DB11853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
Study: NCT03085095
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan, Taiwan, and China), every 3 months by subcutaneous injection
Study: NCT02897830
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).
Study: NCT06781073
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab in combined with chemotherapy period, 400mg, day1, administered intravenously before chemotherapy ,weekly, for 18 weeks; Maintenance period, 400mg, every two weeks until disease progression or intolerable toxicity , maximum duration is 60 weeks .
Study: NCT06781073
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175mg/m\^2,for 3 hour,day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
Study: NCT06781073
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m\^2,day1orday2，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
Study: NCT05043896
Drug: Tadalafil 2.5Mg Tab
Normalized name: TADALAFIL 2.5MG TAB
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tadalafil 2.5mg once daily
Study: NCT04342858
Drug: Fluoride Varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK
Study: NCT01539616
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
Study: NCT01283724
Drug: Dienogest (Visanne, BAY86-5258)
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
Study: NCT00003824
Drug: cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral bid for 3 days starting the night before resection
Study: NCT00003824
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg oral bid for 3 days starting the night before resection
Study: NCT01021423
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.